Research programme: MHCI-directed therapies - Grey Wolf Therapeutics
Latest Information Update: 07 Jun 2024
At a glance
- Originator Grey Wolf Therapeutics
- Class Antineoplastics
- Mechanism of Action ERAP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer